Targeted Aml1-Eto Neoantigen Cytotoxic T Cells
Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation
Explore 15 assets in Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
BGI, China
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06499025CT.gov Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Targeted Aml1-Eto Neoantigen Cytotoxic T Cells (this asset) | BGI, China | Early P1 | C · 39 |
| Etoposide | Alice Mims | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Cytarabine | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Idarubicin | The First Affiliated Hospital of Soochow University | P2 | BBB |
| Cyclophosphamide | BGI, China | P3 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BBB |
| Mitoxantrone | BGI, China | P2 | BBB |
| Fludarabine | Rutgers, The State University of New Jersey | P3 | BB |
+42 more in the Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation cohort
Other indications for Targeted Aml1-Eto Neoantigen Cytotoxic T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | Early P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Targeted Aml1-Eto Neoantigen Cytotoxic T Cells in Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/targeted-aml1-eto-neoantigen-cytotoxic-t-cells-acute-myeloid-leukemia-with-t821q22q22-translocation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →